Generic Drugs a $350 Billion Opportunity According to 'The Generic Drugs Market: 2015-2030 - Opportunities, Challenges, Strategies & Forecasts'

DUBLIN, Mar. 03, 2015 /PRNewswire/ --Research and Markets

(http://www.researchandmarkets.com/research/tvmk72/the_generic_drugs) has announced the addition of SNS Research's new report "The Generic Drugs Market: 2015 - 2030 - Opportunities, Challenges, Strategies & Forecasts" to their offering.

A generic drug is a pharmaceutical product, usually intended to be interchangeable with an innovator product, that is manufactured without a license from the innovator company and marketed after the expiry date of the patent or other exclusive rights.

Already prevalent in the U.S., Europe and much of the developing world, generic drugs are now finding their way into previously untapped markets such as Japan, largely driven by regulatory efforts to reduce healthcare costs.

SNS Research estimates that the market for generic drugs will account for nearly $350 Billion in revenue by the end of 2015. Despite challenges relating to quality control and legal concerns, the market is poised for significant growth in the coming years. The market is expected to grow at a CAGR of 12% between 2015 and 2020, driven by growth in both established and developing markets.

The "Generic Drugs Market: 2015 – 2030 – Opportunities, Challenges, Strategies & Forecasts" report presents an in-depth assessment of the generic drugs ecosystem including technology, economics, key trends, market drivers, challenges, investment potential, regulatory landscape, leading therapies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for generic drugs from 2015 through to 2030. The forecasts are segmented for over 10 therapeutic areas, 3 brand classifications, 5 regions and 25 leading countries.

Key Findings:

- Generic drugs will account for nearly $350 Billion in revenue by the end of 2015. The market is further expected to grow at a CAGR of 12% over the next five years.
- As the market consolidates, larger players continue to grow their market share on the heels of acquisitions and mergers. Well established players are particularly keen to capitalize on joint ventures in untapped markets such as Japan.
- In order to overcome low margins, some generic drug manufacturers are venturing into the super generics opportunity. Sold for a significantly higher price than their pure generic counterparts, super generics account for 18% of all spending on generic drugs.
- In a bid to control costs and expand their global reach, generic drug manufacturers are complementing their existing manufacturing and R&D locations with sites in low cost countries such as India, China and Russia.
- Driven by the cost saving potential of biosimilar drugs, a number of countries have established regulatory pathways for their approval. We estimate that approved biosimilar drugs will account for more than $20 Billion in revenue by the end of 2020.

Key Topics Covered:

Chapter 1: Introduction

Chapter 2: An Overview of Generic Drugs

Chapter 3: Regulatory Landscape

Chapter 4: Drug Class Availability & Leading Therapies

Chapter 5: Generic Drugs Industry Roadmap & Value Chain

Chapter 6: Key Market Players

Chapter 7: Market Analysis & Forecasts

Chapter 8: Conclusion & Strategic Recommendations

Companies Mentioned

• ACETO Corporation
• AMA (African Medicines Regulatory Agency)
• AMRI (Albany Molecular Research, Inc.)
• ASKA Pharmaceutical Company
• AbbVie
• Abbott Laboratories
• Acino Holding
• Actavis
• Actelion
• Adcock Ingram
• Aesica Pharmaceuticals
• Ajinomoto
• Akron
• Alexion Pharmaceuticals
• Alfa Wasserman
• Allergan
• Almirall
• Amgen
• Amneal Pharmaceuticals
• ApoPharma
• Apotex
• Arch Pharmalabs
• Aspen Holdings
• Astellas Pharma
• AstraZeneca
• Aurobindo Pharma
• Auxilium Pharmaceuticals
• BD (Becton, Dickinson and Company)
• BD Rx
• BMS (Bristol-Myers Squibb)
• BPI (Breckenridge Pharmaceutical Inc.)
• Baxter BioScience
• Baxter International
• Bayer AG
• Berlin Chemie
• Biocon
• Biogaran
• Biogen Idec
• Biogen Laboratorios
• Boehringer Ingelheim
• Boots UK
• Breckenridge Pharmaceutical
• CBER (Centre for Biologics Evaluation and Research)
• CDER (Centre for Drug Evaluation and Research)
• CDSCO (Central Drug Standards and Control Organization, India)
• CFDA (China Food and Drug Administration)
• Cadila Healthcare (Zydus Cadila)
• Cadila Pharmaceuticals
• Cedarburg Pharmaceuticals
• Celgene Corporation
• Celltrion Group
• Chiesi Farmaceutici
• Chugai Pharmaceutical Company
• Cipla
• Claris Injectables
• Claris Lifesciences
• Claris Otsuka
• Coherus BioSciences
• Consort Medical
• Covidien
• Cubist Pharmaceuticals
• Cypress Pharmaceutical
• Daiichi Sankyo
• Daiichi Sankyo Espha
• Dong-A Pharmaceutical
• Dr. Reddy's Laboratories
• Dusa Pharmaceuticals
• EGA (European Generic Medicines Association)
• EMA (European Medicines Agency)
• ESTEVE Farma
• ESTEVE Group
• Egis Pharmaceuticals
• Eisai Company
• Eli Lilly and Company
• Elmed Eisai Company
• Endo International
• Endo Pharmaceuticals
• Eurofarma Laboratorios
• FDA (Food and Drug Administration)
• Ferring Pharmaceuticals
• Forest Laboratories
• Fresenius Kabi
• Fuji Pharma Company
• Fujifilm Corporation
• Fujifilm Holdings Corporation
• Fujifilm Pharma Company
• GGL (Glenmark Generics Limited)
• GSK (GlaxoSmithKline)
• Galderma
• Galenika
• Gedeon Richter
• Gedeon Richter PregLem
• Genepharm
• Gilead Sciences
• Glenmark Pharmaceuticals
• Global Pharmaceuticals
• Globalpharma
• Grifols
• Gruenenthal Group
• Guangdong BeiKang Pharmaceutical Company
• Hanmi Pharmaceutical Company
• Health Canada
• Hetero Drugs
• Hi-Tech Pharmacal
• Hikma Pharmaceuticals
• Hospira
• Impax Laboratories
• Impax Pharmaceuticals
• Ipsen
• JHP Group Holdings
• JHP Pharmaceuticals
• JT (Japan Tobacco)
• Janssen Pharmaceutica
• Jazz Pharmaceuticals
• Johnson & Johnson
• Kaken Pharmaceutical Company
• Kaneka Corporation
• Kowa Company
• Kowa Health Care America
• Kowa Pharmaceuticals America
• Kowa Research Institute
• Kremers Urban Pharmaceuticals
• Krka (Krka, d. d.)
• Kyowa Hakko Kirin Company
• Kyowa Pharmaceutical Industry Company
• Laboratorios Roemmers
• Leo Pharma
• Les Laboratoires Servier
• Lil Therapeutics
• Lundbeck (H. Lundbeck A/S)
• Lupin
• MN (Mustafa Nevzat) Pharma
• Mallinckrodt
• Maruho Company
• Matrix Laboratories
• Meda
• Medley Farma
• Meiji Holdings
• Meiji Seika Pharma Company
• Menarini Group
• Merck KGaA
• Merck Serono
• Merck and Co.
• Merz Pharma
• Ministry of Health, Labour and Welfare (Japan)
• Mitsubishi Chemical Holdings Corporation
• Mitsubishi Tanabe Pharma
• Mitsui & Company
• Mitsui Group
• Mylan
• Natco Pharma
• Nichi-Iko Pharmaceutical Company
• Nippon Kayaku
• Nippon Shinyaku
• Nipro Pharma Corporation
• Novartis International
• Novo Nordisk
• OLIC (Thailand)
• Ono Pharmaceutical Company
• Orion Corporation
• Osaka Synthetic Chemical Laboratories
• Otsuka Holdings Company
• Otsuka Pharmaceutical Company
• Paladin Labs
• Par Pharmaceutical Companies
• Pensa Dose
• Pensa Pharm
• Perrigo Company
• Pfizer
• Pharma Dynamics
• Pharmstandard
• Pierre Fabre (Laboratoires Pierre Fabre)
• Piramal Enterprises
• Piramal Group
• Pliva (Pliva d.d.)
• Prasco Laboratories
• PregLem
• Purdue Pharma
• Qualitest and Vintage Pharmaceuticals
• Ranbaxy Laboratories
• Recordati
• Regeneron Pharmaceuticals
• Rising Pharmaceuticals
• Roche Holding (F. Hoffmann-La Roche)
• Roxane Laboratories
• STADA Arzneimittel
• Salix Pharmaceuticals
• Samsung BioLogics
• Samsung Bioepis
• Samsung Group
• Sandoz International
• Sanofi
• Sanofi-Aventis Nichi-Iko K.K.
• Santen Pharmaceutical Company
• Sawai Pharmaceutical Company
• Seikagaku Corporation
• Sequent Scientific
• Servier Group
• Shionogi & Company
• Shire
• Sigma-Tau
• Somar (Grupo Farmaceutico Somar)
• Strativa Pharmaceuticals
• Strides Arcolab
• Sumitomo Dainippon Pharma Company
• Sun Pharmaceutical Industries
• Supera Farma Laboratorios
• Taisho Pharmaceutical Company
• Taisho Pharmaceutical Holdings Company
• Taisho Pharmaceutical Industries
• Taiyo Pharmaceutical Industry Company
• Takeda Pharmaceutical Company
• Tanabe Seiyaku Hanbai Company
• Taro Pharmaceutical Industries
• Teijin
• Teijin Pharma
• Teva Pharmaceutical Industries
• Teva-Kowa Pharma Company
• The Medicines Company
• Torrent Group
• Torrent Pharmaceuticals
• Towa Pharmaceutical Company
• UCB
• United Therapeutics Corporation
• Valeant Pharmaceuticals International
• Ventana Medical Systems
• Vertex Pharmaceuticals
• WHO (World Health Organization)
• Warner-Chilcott
• West-Ward Pharmaceuticals

For more information visit http://www.researchandmarkets.com/research/tvmk72/the_generic_drugs

Source: SNS Research

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets